Should You Buy UnitedHealth Group Stock After Its Steep Sell-Off?

CMS proposed a 2027 Medicare Advantage rate increase of just 0.09%—well below analyst expectations of 4–6%—spurring a sharp market reaction: UnitedHealth shares plunged ~20% (now down >50% from its late‑2024 peak), Humana fell ~22% and CVS ~14%. UnitedHealthcare is the largest Medicare Advantage insurer and the proposed rates, which CMS will finalize in spring, could force benefit cuts and alter product/geographic footprints; Medicare Advantage represents roughly 15% of UnitedHealthcare’s medical membership. Morningstar noted CMS may add ~2.5% later for billing trends, and UnitedHealth still projects modest 2026 growth with low double‑digit earnings growth in 2027 and a return to historical growth in 2028, while management reiterates long‑term 13–16% growth targets.

Analysis

Market structure: The CMS 2027 draft (0.09%) punctures near-term pricing power for Medicare Advantage (MA) heavy players — direct losers: UNH, HUM, CVS (MA/PBM exposure); winners are non-MA focused insurers, pure-play pharma/devices, and beneficiaries who see slower premium growth. Expect narrower managed-care margins in 2026–27, selective market exits in loss-making counties, and potential local consolidation that increases pricing power for surviving incumbents over 12–36 months.

Risk assessment: Tail risks include a worse-than-expected final CMS rule (<0%) or legislative caps that permanently compress MA margins, plus rapid membership churn if benefits are cut — low probability but value-destroying (10–30% EPS downside scenarios). Immediate (days) risk is elevated IV and liquidity; short-term (weeks/months) hinge on CMS finalization (spring 2026) and enrollment trends; long-term (2027–28+) depends on rate normalization or insurer footprint adjustments.

Trade implications: Tactical opportunities center on rates finalization timeline: prefer defined-risk bullish exposure to UNH into spring if you believe a modest upward revision (to ~2–2.5%) arrives. Relative-value: short more MA-concentrated HUM vs UNH/ CVS hedged long; use 1–4 month call spreads on UNH to capture a policy-driven rebound while avoiding unlimited downside if rules deteriorate.

Contrarian angles: The market likely overshot—MA represents ~15% of UNH medical membership, not 50% of value, so a 20% single-day freefall appears disproportionate and creates mispricing. History shows draft CMS moves often revise by 1–3% at final rule; unintended consequence: provider/plan exits could force CMS to lift future rates or spark M&A, creating 12–24 month upside for survivors.

Key Decisions for Investors

• Establish a 2–3% long position in UNH within 10 trading days on any further pullback up to an additional -15% from current post-earnings levels; horizon 6–12 months, trim to half position if CMS final rule ≤0.5% or if position falls >12% (hard stop).
• Initiate a dollar-neutral pair trade: long UNH (2% portfolio) vs short HUM (1.5% portfolio) sized to equal dollar exposure; hold until CMS final rule (expected Mar–Apr 2026) or until relative P/L diverges >8%, at which point close or rebalance.
• Buy asymmetric options kicker: purchase UNH 3-month call spread (buy ~10% OTM, sell ~25% OTM) sized = 0.5% portfolio risk to target ≥2x payoff if UNH rallies 15–25% post-finalization; cap max premium risk to that 0.5%.
• Buy protection / directional short on HUM: allocate 0.5% portfolio to 3-month puts ~7.5% OTM on HUM to capture additional downside if CMS final rule remains weak; exit on CMS revision ≥+1.5% or at 100% realized gain.
• Reduce aggregate insurer exposure by 150–200 bps now and redeploy into pharma/device names or 2–3 year IG corporate bonds (add 1–2% portfolio) to lower regulatory beta while preserving healthcare exposure.